Table 1.
Baseline and clinical characteristics for all patients, survivors and non-survivors
|
All patients |
Survivors |
Non-survivors |
P value | |
|---|---|---|---|---|
| n = 36 | n = 17 | n = 19 | ||
| Demographics |
|
|
|
|
| Birth weight, grams |
740 ± 290 |
745 ± 293 |
736 ± 295 |
0.92 |
| Gender, Male |
19 (53) |
9 (53) |
10 (53) |
1.0 |
| Race |
|
|
|
0.86 |
| Caucasian |
15 (42) |
7 (41) |
8 (42) |
|
| African American |
20 (55) |
9 (53) |
11 (58) |
|
| Hispanic |
1 (3) |
1 (6) |
0 (0) |
|
| Gestational age, weeks |
26.0 ± 1.9 |
26.2 ± 2.4 |
25.8 ± 1.4 |
0.59 |
| Small for gestational age |
13 (36) |
6 (35) |
7 (37) |
1.0 |
| Respiratory support at 36 weeks postmenstrual age |
|
|
|
0.62 |
| Mechanical ventilation |
15 (42) |
8 (47) |
7 (37) |
|
| CPAP |
5 (14) |
1 (6) |
4 (21) |
|
| O2 supplementation |
13 (36) |
7 (41) |
6 (32) |
|
| Room air |
3 (8) |
1 (6) |
2 (10) |
|
| Morbidity |
|
|
|
|
| BPD |
|
|
|
0.61 |
| Mild |
3 (8) |
1 (6) |
2 (10.5) |
|
| Moderate |
2 (6) |
0 (0) |
2 (10.5) |
|
| Severe |
31 (86) |
16 (94) |
15 (79) |
|
| Patent ductus arteriosus |
6 (16) |
6 (35) |
0 (0) |
0.006 |
| Severe intraventricular hemorrhage (grade 3 or 4) |
9 (25) |
6 (35) |
3 (8) |
0.26 |
| Proven necrotizing enterocolitis (stage 2 or 3) |
5 (14) |
4 (24) |
1 (5) |
0.17 |
| Peak BNP, pg/mL |
351 (82,1461) |
128 (23,463) |
997 (278,1770) |
0.004 |
| Medications |
|
|
|
|
| Inhaled nitric oxide |
32 (89) |
13 (76) |
19 (100) |
0.04 |
| Sildenafil |
31 (86) |
12 (71) |
19 (100) |
0.02 |
| Bosentan | 18 (50) | 7 (41) | 11 (58) | 0.51 |
Data shown as n (%), mean ± standard deviation, or median (interquartile range). P values refer to independent samples t-test, Mann–Whitney U, or Fisher’s exact test.
BNP B-type natriuretic peptide, BPD bronchopulmonary dysplasia, CPAP continuous positive airway pressure, O 2 oxygen.